Company news
Guardant Health, Inc. news in 2023
Guardant Health, Inc.'s news releases, calls and decks from 2023, newest first.
Guardant Health Announces $90.7 Million Registered Direct Offering with Baillie Gifford
December 20, 2023
Guardant Health to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 19, 2023
Guardant Health Announces Tentative Date of FDA Advisory Panel Review of Shield™ Blood Test
December 18, 2023
Cancer Research UK and Guardant Health Launch Collaboration to Advance Cancer Research and Clinical Development Activities
December 3, 2023
Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection
November 29, 2023
Guardant Health to Appeal Federal District Court Verdict
November 14, 2023
Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea
November 11, 2023
Guardant Health Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
November 5, 2023
Guardant Health to Participate in Upcoming November Investor Conferences
November 2, 2023
Guardant Health, Flatiron Health Announce Integration of Guardant Genomic Profiling Tests Into OncoEMR® Platform
October 30, 2023
Guardant Health to Report Third Quarter 2023 Financial Results on November 6, 2023
October 15, 2023
Guardant Health Receives Coverage for Guardant Reveal™ from Geisinger Health Plan
September 5, 2023
Guardant Health Receives Regulatory Approval in Japan for Guardant360® CDx as Companion Diagnostic to ENHERTU® for Treatment of Non-Small Cell Lung Cancer Patients with HER2 Mutations
September 4, 2023
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
August 31, 2023
Guardant Health to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
August 30, 2023
Guardant Health to Host Investor Day on September 7, 2023
August 16, 2023
Guardant Health Reports Second Quarter 2023 Financial Results and Increases Revenue Guidance
August 2, 2023
Guardant resolves pending litigation with Illumina and enters into new agreement to advance long-term commercial partnership and cancer research
July 31, 2023
Guardant Health receives first commercial payor coverage for Guardant Reveal™ test from Blue Cross and Blue Shield of Louisiana
July 19, 2023
Guardant Health to Report Second Quarter 2023 Financial Results on August 3, 2023
July 11, 2023
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
July 4, 2023
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
May 30, 2023
Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers
May 28, 2023
Guardant Health to Participate in Upcoming June Investor Conferences
May 25, 2023
Guardant Health Secures Coverage From Major US Commercial Health Insurers for Guardant360® Blood Test for Comprehensive Genomic Profiling
May 16, 2023
Guardant Health Releases Inaugural ESG Report
May 15, 2023
Guardant Health Reports First Quarter 2023 Financial Results
May 8, 2023
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
May 8, 2023
Guardant Health Announces Additions to Leadership Team
May 7, 2023
Guardant Health Announces ECLIPSE Study Update Call on May 9, 2023
May 4, 2023
Guardant Health to Participate in the BofA Securities 2023 Healthcare Conference
April 26, 2023
Guardant Health and Parker Institute for Cancer Immunotherapy (PICI) launch research collaboration to study connection between cancer biomarkers and immunotherapy treatment response
April 24, 2023
Guardant Health announces new data to be presented at 2023 Digestive Disease Week showcasing the potential of its blood-based technology to detect colorectal cancer
April 20, 2023
Guardant Health to Report First Quarter 2023 Financial Results on May 9, 2023
April 18, 2023
Guardant Health Receives Medicare Coverage for Guardant360 Response™ to Monitor Cancer Patient Response to Immunotherapy
April 17, 2023
Guardant Health to Present Data From 14 Studies Highlighting Advances in Precision Oncology and Cancer Screening at 2023 AACR Annual Meeting
April 10, 2023
Guardant Health collaborates with The Ohio State University Comprehensive Cancer Center to study colorectal cancer screening adherence
March 20, 2023
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
March 9, 2023
Musa Tariq Joins Guardant Health Board of Directors
February 26, 2023
Guardant Health Reports Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Outlook
February 22, 2023
Guardant Health to Participate in Upcoming March Investor Conferences
February 16, 2023
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
February 14, 2023
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
February 7, 2023
Magistrate Judge Issues Favorable Recommendation Regarding Guardant Health’s Motion to Dismiss Lawsuit Brought by Illumina
February 1, 2023
Guardant Health and AnHeart Therapeutics Announce Collaboration to Develop Guardant360® CDx and Guardant360 TissueNext™ as Companion Diagnostics for Taletrectinib in Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
February 1, 2023
Guardant Health to Report Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023
January 31, 2023
Guardant Health introduces Guardant GalaxyTM suite of advanced AI analytics to enhance its portfolio of cancer tests and accelerate biomarker discovery
January 30, 2023
Guardant Health receives FDA approval for Guardant360® CDx as companion diagnostic for Menarini Group’s ORSERDU™ for treatment of patients with ESR1 mutations in ER+, HER2- advanced or metastatic breast cancer
January 29, 2023
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
January 18, 2023
Guardant Health to showcase new data at ASCO GI 2023 demonstrating utility of its blood tests for patients with gastrointestinal cancers
January 16, 2023
Calls in 2023
Decks in 2023
- Jefferies London Healthcare Conference 2023
Conference · 28 slides · Nov 16, 2023
- Q3 2023 Earnings Presentation
Earnings · 17 slides · Nov 6, 2023
- Investor Day (September 2023)
Investor day · 165 slides · Sep 7, 2023
- Q2 2023 Earnings Presentation
Earnings · 18 slides · Aug 3, 2023
- William Blair 43rd Annual Growth Stock Conference 2023
Conference · 26 slides · Jun 6, 2023
- Q1 2023 Earnings Presentation
Earnings · 20 slides · May 9, 2023
- Q4 2022 Earnings Presentation
Earnings · 19 slides · Feb 23, 2023
- J.P. Morgan Healthcare Conference 2023
Conference · 40 slides · January 2023